Androgenic Alopecia Treatment
OLX104C is developed to delay the progression of androgenic alopecia by inhibiting the expression of androgen receptors (AR).
The therapeutics is expected to have high commercial value as it demonstrates long-term efficacy while minimizing side effects of existing drugs such as sexual dysfunction and restricted use on women.
Target RNA: Androgen Receptor (AR)
Administration Route: Intradermal Injection
Androgenic Alopecia (AGA)
Androgenic alopecia results from male hormone response. Testosterone is converted into dihydrotestosterone (DHT) by 5-alpha reductase, and its binding with androgen receptors leads to reduced follicles to change in the hair growth cycle, ultimately causing hair growth to cease.
- Efficient inhibition of AGA identified in animal models and hair follicles
- Patent granted (US, Japan, Korea)
- Phase 1 clinical trial IND approved (Australia) (23.03)
- 2021 Korean Hair Research Society – Hair Forum (21.05)
- 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
- 2022 Molecular Pharmaceutics (22.11)